Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v6-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2022-02-09 | 2022-02-09 |
| Drug Identification Number | 02510162 | 02510162 |
| Brand name | XARELTO | XARELTO |
| Common or Proper name | RIVAROXABAN | RIVAROXABAN |
| Company Name | BAYER INC | BAYER INC |
| Ingredients | RIVAROXABAN | RIVAROXABAN |
| Strength(s) | 51.7MG | 51.7MG |
| Dosage form(s) | GRANULES FOR SUSPENSION | GRANULES FOR SUSPENSION |
| Route of administration | ORAL | ORAL |
| Packaging size | 100ML | 100ML |
| ATC code | B01AF | B01AF |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-02-09 | 2022-02-09 |
| Actual start date | 2022-02-08 | |
| Estimated end date | 2022-03-01 | 2022-03-01 |
| Actual end date | 2022-02-08 | |
| Shortage status | Avoided shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Reason for shortage: Disruptions in Supply chain. | Reason for shortage: Disruptions in Supply chain. |
| Health Canada comments |